biote Corp. (BTMD) stock
BTMDNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
$1.06+0.03 (+3.40%)
Close on Nov 13, 2026Market cap $38.26MP/E –Yield –
biote EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
biote's EPS for the twelve months ending Sep 30, 2026 was -$0.11, down 113.9% year over year. For fiscal 2025 it was $0.74, up 722.2% from the year before.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0.74 | +722.2% |
| FY2024 | Dec 31, 2024 | $0.09 | -30.8% |
| FY2023 | Dec 31, 2023 | $0.13 | – |
| FY2022 | Dec 31, 2022 | -$0.12 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $0.01 | -95.5% |
| Q2 FY2026 | Jun 30, 2026 | -$0.23 | -330.0% |
| Q1 FY2026 | Mar 31, 2026 | $0.06 | -83.8% |
| Q4 FY2025 | Dec 31, 2025 | $0.05 | -50.0% |
| Q3 FY2025 | Sep 30, 2025 | $0.22 | -33.3% |
| Q2 FY2025 | Jun 30, 2025 | $0.10 | – |
| Q1 FY2025 | Mar 31, 2025 | $0.37 | – |
| Q4 FY2024 | Dec 31, 2024 | $0.10 | -58.3% |
| Q3 FY2024 | Sep 30, 2024 | $0.33 | – |
| Q2 FY2024 | Jun 30, 2024 | -$0.21 | – |
| Q1 FY2024 | Mar 31, 2024 | -$0.12 | -170.6% |
| Q3 FY2023 | Sep 30, 2023 | $0.24 | – |
| Q2 FY2023 | Jun 30, 2023 | -$0.25 | – |
| Q1 FY2023 | Mar 31, 2023 | -$0.39 | – |
| Q4 FY2022 | Dec 31, 2022 | $0.17 | – |
| Q3 FY2022 | Sep 30, 2022 | $0.00 | – |
| Q2 FY2022 | Jun 30, 2022 | -$0.34 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?